Page 91 - AN-3-2
P. 91

Advanced Neurology                                          Genetics of neurodevelopmental disorders in Mexico




            Table 1. (Continued)
            No. Gender Age of   Epilepsy ASD ADHD CD MD ID Dysmorphism  Dysfunction   Definitive diagnosis  Familial
                      onset                                                           (Gene)        study
            22 β  F   1 year    X                      X Facial and limb   Intellectual disability  No genetic diagnosis  -
                                                          dysmorphism                 (TANGO carrier,
                                                                                      VUS)
            23 β  M   At birth  X    X         X       X Macrosomia    Intellectual disability  No genetic diagnosis  -
                                                                                      (pseudogene GALC
                                                                                      carrier)
            24 β  M   At birth             X   X          Coloboma,    Arrhythmia     CHARGE syndrome  -
                                                          microtia,                   (no mutation
                                                          thumb anomaly,              detected) FANCF
                                                          congenital heart            (pseudogene carrier)
                                                          disease
            T   15 M9 F -       11   11    6   18  11  6  -                           -             11 families
                                                                                                    30 members
            Notes:  Cases that had a definitive diagnosis with the study;  cases with variants of uncertain significance (VUS) related to the clinical presentation;
                                                  δ
                 θ
            β cases in which the study ruled out the Mendelian diseases most frequently associated with their clinical presentations.
            Abbreviations: ASD: Autism spectrum disorder; ADHD: Attention deficit hyperactivity disorder; CD: Communication disorder; ID: Intellectual
            disability; MD: Motor disorder; UPD: Uniparental disomy.
              Eleven  patients with NDDs  and  epilepsy  were   and there is a cousin with similar signs. The homozygous
            studied, and a genetic diagnosis was confirmed in nine   mutation of CFRL1 c.151_153del (p.Leu51del) is described
            of them (81.8%). Among the five patients diagnosed   as a benign polymorphism combined with a likely benign
            with  ASD  and  epilepsy,  four  exhibited  mutations  in   mutation in  HCN1 c.192_206dup (p.Gly70_Gly74dup),
            SYNGAP1,  CDKL5,  MECP2,  and  CRLF1.  A  heritable,   which is heterozygous and inherited from the father.
            yet likely benign mutation in HCN1 was also identified,   Patient 7, who exhibited motor delay, visual and
            manifesting as febrile crises in both the father and the   auditory  impairments,  epilepsy,  and  lacked  verbal
            patient. In addition, a VUS was detected in  SNCA8.   language  capabilities,  was born from  a  consanguineous
            Mutations in  PTEN,  PURA,  PNPT1,  NF1, and six   marriage that previously resulted in a stillbirth diagnosed
            VUSs were identified across conditions including ASD,   with a genetic condition due to a homozygous mutation
            communication disorders, and ADHD. NDDs and motor   in DUOX2, that is, c.2182 G>A (p.Ala728Thr). The second
            disabilities  were associated with mutations in  PNPT1,   daughter  carries a  homozygous  pathogenic  mutation in
            DMD,  LAMP2,  and  COLQ.  These  findings  are  detailed   PNPT1, that is, c.407G>A (p.Arg136His), associated with
            in Table 2, which correlates specific genes with diagnoses   autosomal recessive combined oxidative phosphorylation
            and parental origins, following the study of the patient’s   deficiency 13 (COXPD13). Patient 14 was diagnosed
            relatives. In six patients, we identified genetic syndromes   with PURA syndrome, characterized by the absence of
            with very low prevalence caused by novel mutations,   verbal language, long palpebral fissures, curly eyelashes,
            including conditions related to SYNGAP1 synaptopathy,   and drop-shaped fingertips. Patient 15 presented at birth
            PURA syndrome, and mutations in  CDKL5,  MECP2,    with a clinical picture suggestive of congenital amyoplasia,
            and  PTEN. In addition, two heritable conditions   caused by a pathogenic exonic mutation in  COLQ,
            were  diagnosed  in  consanguineous  parents:  Crisponi   which leads to myasthenic syndrome (MIM 603034).
            syndrome/cold-induced sweating syndrome and an     The etiopathogenesis of this syndrome is intriguing, as
            oxidative phosphorylation defect. These atypical cases are   it is thought to be related to a vascular disruptive event
            noteworthy and merit reporting.                    in the first trimester of gestation, under the influence of
              Patient 4, with Crisponi syndrome or cold-induced   susceptibility genes.
            sweating,  presented  the  classical  neonatal-onset  clinical   In several patients, we detected pathogenic heterozygous
            picture with crying, camptodactyly, disorders for   mutations associated with recessive diseases, as detailed in
            sucking, swallowing, feeding, the episodes of sweating   Table 3. This information is particularly valuable for suspecting
            induced by cold and body temperature dysregulation,   congenital pathologies  in contexts of  consanguinity and
            and hyperthermia of unspecified cause described in the   endogamy prevalent in the region. The diseases identified
            syndrome.  The parents of this patient are consanguineous,   in  a  carrier  state  include  biotinidase  deficiency  (BTD),
                    14

            Volume 3 Issue 2 (2024)                         5                                doi: 10.36922/an.3359
   86   87   88   89   90   91   92   93   94   95   96